The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention

Aslanabadi, Naser; Safaie, Naser; Asgharzadeh, Yousef; Houshmand, F; Ghaffari, Samad; Garjani, Alireza; Dousti, Samaneh; Hamishehkar, Hadi; Entezari‐Maleki, Taher

doi:10.1111/1755-5922.12195

Cited by 11 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized, clinical trial, the intervention group of 50 patients received a 300 mg loading dose COQ10 12 hours before the procedure. No significant change was reported in the level of cardiac biomarkers but there was a significant reduction in high sensitive C-reactive peptide level in COQ10 group [146]. This supports the evidence that COQ10 attenuates inflammatory reactions.…”

Section: Cardiac Surgery and Percutaneous Coronary Interventionsupporting

confidence: 67%

Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem

Zozina

Covanţev

Goroshko

et al. 2018

CCR

131

View full text Add to dashboard Cite

The burden of cardiovascular and metabolic diseases is increasing with every year. Although the management of these conditions has improved greatly over the years, it is still far from perfect. With all of this in mind, there is a need for new methods of prophylaxis and treatment. Coenzyme Q10 (CoQ10) is an essential compound of the human body. There is growing evidence that CoQ10 is tightly linked to cardiometabolic disorders. Its supplementation can be useful in a variety of chronic and acute disorders. This review analyses the role of CoQ10 in hypertension, ischemic heart disease, myocardial infarction, heart failure, viral myocarditis, cardiomyopathies, cardiac toxicity, dyslipidemia, obesity, type 2 diabetes mellitus, metabolic syndrome, cardiac procedures and resuscitation.

show abstract

Section: Cardiac Surgery and Percutaneous Coronary Interventionsupporting

confidence: 67%

Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem

Zozina

Covanţev

Goroshko

et al. 2018

CCR

131

View full text Add to dashboard Cite

show abstract

“…The second trial among 100 patients showed that 300 mg coenzyme Q10 12 hours before elective PCI could not reduce PMI. However, it significantly decreased hs‐CRP …”

Section: Discussionmentioning

confidence: 92%

“…24 Recently in 2 randomized trials, we evaluated the effect of 1200 mg pentoxifylline and 300 mg coenzyme Q10 for the prevention of myocardial injury following elective PCI. 25,26 In the first trial, a loading dose of 1200 mg pentoxifylline before elective PCI in 85 patients could not lead to a significant result. 25 The second trial among 100 patients showed that 300 mg coenzyme Q10 12 hours before elective PCI could not reduce PMI.…”

Section: Comparison With Other Trialsmentioning

confidence: 99%

Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial

Aslanabadi

Jafaripor

Sadeghi

et al. 2017

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Myocardial injury following elective percutaneous coronary intervention (PCI) occurs in about one-third of patients and is associated with mortality. Platelet aggregation, thrombosis formation, and inflammation are the main causes of cardiac injury during PCI. Vitamin D plays a key role in the cardiovascular system by exerting antiplatelet, anticoagulant, and anti-inflammatory properties. There is no published study that investigated the effect of vitamin D in the prevention of cardiac injury following elective PCI. In a randomized clinical trial, 99 patients admitted for elective PCI were randomized into vitamin D (n = 52) and control (n = 47) groups. The intervention group received 300 000 IU vitamin D orally 12 hours before PCI. The cardiac biomarkers were checked at baseline, 8 and 24 hours after PCI. hs-CRP was also measured at baseline and after 24 hours. The increase in CK-MB was documented in 20 patients (42%) in the control group and 18 patients (34.6%) in the intervention group (P = .417). Furthermore, the increase in cTnI occurred in 4 patients (8%) and 2 patients (3.3%) in the control and intervention groups, respectively (P = .419). No significant changes were noted in the level of cardiac biomarkers. In the vitamin D group, the mean difference in CK-MB between 8 and 24 hours was significantly lower (P = .048). The mean difference in hs-CRP was significantly lower in the vitamin D group (P = .045). This study could not show a clear effect of vitamin D in the prevention of cardiac injury during elective PCI. Further outcome-based studies are needed to describe the role of vitamin D in the prevention of periprocedural myocardial injury.

show abstract

“…All showed a beneficial effect except one [ 74 ]. In this particular study, patients were pretreated with 300 mg CoQ10 only 12 h before the procedure and a reduction of the preprocedural myocardial injury following elective percutaneous coronary intervention was not observed, although the hs-C reactive protein significantly decreased [ 28 ]. This lack of effectiveness in the treatment with CoQ10 may be due to an insufficient increase in the plasma levels of CoQ10 since plasma ubiquinol concentration had nearly reached a steady state by 2 weeks after the beginning of the treatment [ 55 , 74 ].…”

Section: Coq10 In Cardiac Surgery and Coronary Arterial Disease (Cad)mentioning

confidence: 99%

The Use of Coenzyme Q10 in Cardiovascular Diseases

Llanos-González

Alcaı́n

2021

Antioxidants

View full text Add to dashboard Cite

CoQ10 is an endogenous antioxidant produced in all cells that plays an essential role in energy metabolism and antioxidant protection. CoQ10 distribution is not uniform among different organs, and the highest concentration is observed in the heart, though its levels decrease with age. Advanced age is the major risk factor for cardiovascular disease and endothelial dysfunction triggered by oxidative stress that impairs mitochondrial bioenergetic and reduces NO bioavailability, thus affecting vasodilatation. The rationale of the use of CoQ10 in cardiovascular diseases is that the loss of contractile function due to an energy depletion status in the mitochondria and reduced levels of NO for vasodilatation has been associated with low endogenous CoQ10 levels. Clinical evidence shows that CoQ10 supplementation for prolonged periods is safe, well-tolerated and significantly increases the concentration of CoQ10 in plasma up to 3–5 µg/mL. CoQ10 supplementation reduces oxidative stress and mortality from cardiovascular causes and improves clinical outcome in patients undergoing coronary artery bypass graft surgery, prevents the accumulation of oxLDL in arteries, decreases vascular stiffness and hypertension, improves endothelial dysfunction by reducing the source of ROS in the vascular system and increases the NO levels for vasodilation.

show abstract

The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention

Cited by 11 publications

References 36 publications

Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem

Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem

Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial

The Use of Coenzyme Q10 in Cardiovascular Diseases

Contact Info

Product

Resources

About